Last reviewed · How we verify
35 kDa hyaluronan fragment HA35 injection
At a glance
| Generic name | 35 kDa hyaluronan fragment HA35 injection |
|---|---|
| Also known as | HA35 |
| Sponsor | Nakhia Impex LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- 35 kDa Hyaluronan Fragment (HA35) Reduces Chronic Inflammation of Skin (NA)
- Local Injection of Periodontal Pocket Method for the Treatment of Gingivitis (NA)
- Local Injection for the Treatment of Chronic Wounds and Pain Caused by Chronic Wounds (NA)
- HA35 Treatment the Gingival Discomfort as Well as Gingival Redness and Bleeding of Patients With Periodontitis (NA)
- Injection Therapy for Neuropathic Pain (NA)
- Freshly Manufactured 35kDa Hyaluronan Fragment HA35 for the Treatment of Chronic Wounds (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 35 kDa hyaluronan fragment HA35 injection CI brief — competitive landscape report
- 35 kDa hyaluronan fragment HA35 injection updates RSS · CI watch RSS
- Nakhia Impex LLC portfolio CI